SINTX Technologies Secures New US Patent, Bolstering Its Advanced Ceramics Leadership
$SINT
SINTX Technologies, Inc. (NASDAQ:SINT), a pioneer in advanced ceramics specializing in silicon nitride applications for medical and technical uses, has announced a significant enhancement to its intellectual property portfolio with the issuance of US Patent No. 12,239,761. This patent, granted by the United States Patent and Trademark Office (USPTO), marks a notable advancement in the processing and application of silicon nitride, particularly within the biomedical sector.
The Salt Lake City-based company, known for its innovative approach to next-generation implant technology, has developed methods to adhere silicon nitride to various biomaterial substrates. This breakthrough aims to improve biocompatibility and infection resistance, broadening the potential uses of silicon nitride in medical fields such as orthopedics, craniomaxillofacial, dental and spinal implants.
Eric K. Olson, President and CEO of SINTX, expressed the company’s commitment to advancing silicon nitride technology. “This patent represents another key milestone in our ongoing commitment to pioneering advanced silicon nitride solutions,” Olson stated. He highlighted the material’s antiviral, antibacterial and biomechanical properties, which continue to show promise in medical implants, regenerative medicine and advanced coating technologies.
SINTX is distinguished as the only FDA-registered producer of implantable silicon nitride, boasting a robust portfolio that includes monolithic ceramic implants, particulate-based coatings, microspheres and composite materials. These innovations are designed to enhance osseointegration and reduce bacterial colonization, which are crucial for improving implant longevity and patient safety.
With the new patent, SINTX’s intellectual property portfolio has grown to include 17 issued US patents and 84 pending applications worldwide. This expansion underscores the company’s role as a global leader in silicon nitride research and development. Since 2008, SINTX’s products have been successfully implanted in humans, demonstrating the practical application and reliability of its technologies.
SINTX’s leadership in the field but also enhances its capability to develop high-performance biomedical applications, aligning with its broader mission to leverage proprietary technology to improve patient outcomes and surgical success rates. The company’s ongoing research and development in silicon nitride technology are set to provide significant contributions to the advancement of medical treatments and the enhancement of patient care quality.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**
